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Ashok Srinivasan,1,2 Kimberly A. Kasow,3 Shane Cross,4 Melissa Parrish,5 Chong Wang,6
Deo K. Srivastava,6 Xiangjun Cai,7 John C. Panetta,7 Wing Leung1,2The maximum tolerated dose of palifermin, a keratinocyte growth factor, in children is not known, and its
pharmacokinetics in this population has not been well studied. This is a phase I study of palifermin was de-
signed to evaluate its tolerability at doses of 40, 60, and 90 mg/kg/day in children age 2-18 years of age, re-
ceiving a myeloablative preparative regimen for allogeneic hematopoietic stem cell transplantation
(HSCT). In each cohort, palifermin was given for 3 consecutive days before the preparative regimen and
for 3 days after the stem cell infusion. Twelve patients were enrolled. Palifermin 90 mg/kg/day was tolerated
in 6 patients without dose-limiting toxicity. All patients had at least 1 adverse event, mostly National Cancer
Institute grade 1 or 2 severity. Skin rash, grade 2 or lower, was the most common adverse event, seen in 67%
of patients. Only 3 patients (25%) had mucositis. The area under the concentration–time curve increased
proportionally to the dose, and approximately 97% of palifermin exposure occurred in the first 24 hours af-
ter administration. Palifermin clearance increased linearly with body weight, supporting dosing by body
weight. The mean clearance was 1893 mL/hour/kg, and it did not change significantly between administration
of the first and last doses (P 5 .80). The mean elimination half-life was 4.6 hours. Our data show that pali-
fermin was tolerated at a dose of 90 mg/kg/day, and exhibits linear pharmacokinetics in children undergoing
allogeneic HSCT.
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Mucositis is a major factor contributing tomorbid-
ity andmortality in patients undergoing hematopoietic
stem cell transplantation (HSCT), commonly develop-
ing after radiation-based conditioning regimens [1,2].
As a consequence of damage to the oral, esophageal,
gastric, and colonic mucosa, HSCT recipients may
require i.v. analgesia and total parenteral nutrition.
Mucositis secondary to radiation and chemotherapy
predisposes to systemic infections and graft-versus-
host disease (GVHD) [3].
Palifermin (recombinant human keratinocyte
growth factor [KGF]; Kepivance; Biovitrium, Stock-
holm, Sweden) was approved in December 2004 by
the U.S. Food and Drug Administration for the pre-
vention of mucositis in adults with hematologic
malignancies receiving myeloablative radiation and
chemotherapy with stem cell support. KGF receptorDepartment of BoneMarrowTransplantation and Cellu-
erapy, St. Jude Children’s Research Hospital, Memphis,
essee; 2Department of Pediatrics, University of Tennessee
h Science Center, Memphis, Tennessee; 3Department of
trics, Division of Pediatric Hematology-Oncology, Uni-
y of North Carolina School of Medicine, Chapel Hill,
Carolina; 4Pharmacy; 5Bone Marrow Transplantation
ellular Therapy Clinical Research Office; 6Department
statistics; and 7Department of Pharmaceutical Sciences,
de Children’s Research Hospital, Memphis, Tennessee.is 1 of 4 fibroblast growth factors expressed on epithe-
lial cells of the gastrointestinal system, liver, lung, pan-
creas, bladder, and skin, but not on hematopoietic cells
[4]. Palifermin affects epithelial cell differentiation,
proliferation, and growth, resulting in increased thick-
ness of the epithelial mucosa in the oral mucosa and
gastrointestinal tract [5]. Preclinical murinemodels in-
dicate that recombinant KGF is highly protective for
gastrointestinal [6] and pulmonary toxicity [7] in
mice receiving radiation and chemotherapy, and may
have beneficial effects in ameliorating GVHD [8].
Peritransplantation administration of palifermin has
been shown to improve thymopoiesis and speed im-
mune reconstitution in rodents [9,10] and nonhuman
primates [11].
Clinically, palifermin at a dose of 60 mg/kg/day has
been shown to reduce the incidence and duration of
severe oral mucositis in adult patients with hemato-
logic malignancies undergoing autologous HSCTFinancial disclosure: See Acknowledgments on page 1314.
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data on palifermin treatment in children and adoles-
cents are limited, and palifermin dosing has not been
established in the pediatric setting.
The objectives of this prospective Phase I study
were to (1) determine the maximum tolerated dose
(MTD) of palifermin, evaluating its use at 3 dose levels
(below, at, and above the recommended adult dose), (2)
describe the nonhematologic toxicities related to pali-
fermin administration in children with hematologic
malignancies undergoing a first HSCT, and (3) study
the pharmacokinetics of palifermin at each dose level.METHODS
Study Population
The study was conducted at St. Jude Children’s Re-
search Hospital in Memphis, Tennessee, and was ap-
proved by the hospital’s Institutional Review Board.
Consent was obtained from all parents/guardians, and
assent was obtained from all children age.7 years.
Eligibility criteria included age $2 to\18 years,
a diagnosed hematologic malignancy, and scheduled
to receive a bone marrow stem cell graft from a 5/6
or 6/6 HLA allele-matched related or unrelated donor
after a total body irradiation (TBI)- and cyclophospha-
mide (Cy)-based preparative regimen. Patients had to
have adequate renal, hepatic, cardiac, and pulmonary
function as determined by institutional guidelines. Ex-
clusion criteria included oral ulcerations and gastroin-
testinal bleeding active or within 30 days of
enrollment; known hypersensitivity to Eschericia coli–
derived proteins; any active bacterial, fungal, or viral
infection within 2 weeks before enrollment; and previ-
ous autologous or allogeneic HSCT. All patients had
a performance score of 100.
Patients with a matched sibling donor (MSD) re-
ceived conditioning with Cy 60 mg/kg/day on days
26 and 25 and 12 Gy TBI in 8 fractions of 150 cGy
each given twice daily on days24 to21. GVHD pro-
phylaxis was given with cyclosporine starting on day
22 and mycophenolate mofetil starting on day 0. Pa-
tients with amatched unrelated donor (MUD) received
conditioning with 12 Gy TBI on days28 to25, thio-
tepa 5 mg/kg/dose twice daily on day 24, Cy 60 mg/
kg/day on days 23 and 22, and rabbit antithymocytic
globulin 3 mg/kg/day on days23 to21. GVHD pro-
phylaxis included a calcineurin inhibitor starting on
day 22 and pentostatin 1 mg/m2 given on days 11,
13, and 16 in 8 patients, and tacrolimus, sirolimus,
and methotrexate in 1 patient. Methotrexate was given
at doses of 15 mg/m2 on day11 and 10 mg/m2 on days
13, 16, and111. Patients at risk for cytomegalovirus
or herpes simplex virus reactivation received prophy-
laxis with acyclovir, and all patients received prophy-laxis with metronidazole, co-trimoxazole, and
micafungin in accordancewith institutional guidelines.
Palifermin Dose Schedule
Palifermin was administered as an i.v. bolus once
daily for 3 consecutive days before the start of the con-
ditioning regimen (days 29 to 27 for MSD HSCT
and days211 to29 for MUDHSCT) and for 3 addi-
tional daily doses on days 11, 12, and 13. The drug
was given at 3 dose levels of 40 mg, 60 mg, and 90 mg/
kg/day to 3 patients each, with progression to the
next dose level if no patient experienced a dose-
limiting toxicity (DLT) at the previous dose level. Pa-
tients were dosed by actual body weight.
Pharmacokinetic Testing
Blood samples for pharmacokinetic testing were
obtained at approximately 1, 3, and 6 hours after ad-
ministration of the first dose of palifermin; 24 hours af-
ter administration of the third dose; and 1, 3, 6, 8, 12,
and 24 hours after administration of the last dose on
day13. Samples were also obtained before administra-
tion of each dose. The samples were spun, and sera
were cryopreserved, batched, and run at a later date.
Serum palifermin concentrations were measured
with the Quantikine Kit (R&D Systems, Minneapolis,
MN), which uses the quantitative sandwich enzyme
immunoassay technique. All of the reagents used in
the assay, including the standard KGF and microplate,
were provided with the kit. The sandwich enzyme im-
munoassay plates were coated with a monoclonal anti-
body specific for palifermin. After 100 mL of sample or
standard was pipetted into the wells, the plates were in-
cubated for 3 hours at room temperature. Palifermin
present in the samples was bound by the immobilized
antibody during incubation. After any unbound sub-
stances were washed away, an enzyme-linked poly-
clonal antibody specific to palifermin was added to
the wells. After a wash to remove any unbound
antibody-enzyme reagent, a stabilized tetramethylben-
zidine solution was added to the wells. Color devel-
oped in proportion to the amount of palifermin in
the samples. The intensity of the color was measured
at 450 nm with a BioTek plate reader (BioTek,
Winooski, VT). The wavelength correction was set
at 540 nm. All samples, standards, and controls were
run in duplicate. A calibration curve was included in
each plate. The calibrators had the following concen-
trations of KGF: 0 (blank), 62.5, 125, 250, 500, 1000,
2000, and 3000 pg/mL. For those samples with con-
centrations exceeding the upper range, dilution with
calibrator diluent was required. The validated assay
linear range was 62.5-3000 pg/mL. The clinically re-
portable concentration range was 62.5-40,000 pg/
mL. Intraday precisions were 8.9% at 100 pg/mL
and 9.6% at 650 pg/mL. Interday precision was
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ery was 75% at 1000 pg/mL and 77.6% at 100 pg/mL.
Pharmacokinetic Data Analysis
The population pharmacokinetic and individual
post hoc estimates were derived using nonlinear
mixed-effects modeling analysis performed with
Monolix version 3.1 (www.monolix.org). A one-
compartment pharmacokinetic model with first-order
elimination was fit to the data. Parameters estimated
included systemic clearance (mL/hour or mL/hour/
kg) and volume of distribution (mL or mL/kg). The
distribution of the parameters was assumed to be log-
normal, and both interindividual and interoccasion
variability weremodeled. A proportional residual error
model was used with assumed normal distribution of
the residuals. Estimates of area under the concentra-
tion curve from 0-24 hours (AUC0-24; ng/hour/mL)
were determined using the individual post hoc esti-
mated concentration–time curves.
The effects of weight and day of treatment (day
211/29 versus day 13) on the pharmacokinetic pa-
rameters were analyzed. These covariates were consid-
ered significant in a univariate analysis if their addition
to the model reduced the objective function value by at
least 3.84 units (P\ .05, based on the c2 test for the
difference in the 22 log-likelihood between 2 hierar-
chical models that differ by 1 degree of freedom), and
the covariate term was significantly different than
0 (P\ .05, t test).
Toxicity
Maximum DLT was defined as a grade IV
life-threatening, nonhematologic toxicity definitely
attributable to study drug administration from the first
dose of palifermin up to day 16 after HSCT. Adverse
events and toxicities due to palifermin were assessed
using the National Cancer Institute Common Termi-
nology Criteria for Adverse Events, version 3.0, from
the day the first dose was administered to day16 after
HSCT. Grade 1 mucositis was characterized by ery-
thema of the oral mucosa; grade 2, by patchy mucosal
ulceration; grade 3, by confluent ulceration; grade 4,
by tissue necrosis or significant spontaneous bleeding;
and grade 5, by death. Oral mucositis was assessed
daily during hospitalization. Assessment of mucositis
in all patients was confirmed by the study’s principal
investigator (A.S.).
GVHD was assessed weekly during the first 100
days after HSCT, in accordance with published crite-
ria [13]. Daily physical examination and blood testing,
including complete blood count and serum chemis-
tries, were obtained from the day of the first dose of
palifermin to day 16 post-HSCT, 3 days after the
last dose. As an indirect measure of the severity of mu-
cositis, information on the median number of days of
receipt of total parenteral nutrition (TPN) and themedian narcotic usage of morphine equivalents within
the first 100 days post-HSCT was collected from elec-
tronic pharmacy records.
Statistical Design
The MTD was determined using a Phase I study
design with cohorts of 3 patients each. The first cohort
was treated as the dose level of 40 mg/kg/day. If no tox-
icity related to the drug was seen within 14 days post-
transplantation, then the next cohort of 3 patients
received 60 mg/kg/day. If 1 patient exhibited unaccept-
able toxicity, then an additional cohort of 3 patients
were treated at the same dose level. The dose was esca-
lated to 90 mg/kg/day if no more than 1 episode of tox-
icitywas observed in 6 patients treated at that dose level.
The MTD was defined as the dose level immedi-
ately below the level at which 2 patients out of a cohort
of 3-6 patients experienced a DLT. If no patient expe-
rienced a DLT at any of the dose levels, then another
cohort of 3 patients were treated at the highest dose
level of 90 mg/kg/day. Patients were enrolled in the
study between October 2007 and December 2010.
All patients received the doses of palifermin as sched-
uled. No patient was lost to follow-up. SAS version
9.2 (SAS Institute, Cary, NC) and StatXact (Cytel,
Cambridge, MA) Windows version 8 were used for
statistical analysis.RESULTS
A total of 12 patients (7 females and 5 males; mean
age, 9.2 years; range, 2-16 years; median, 9 years) were
enrolled in the study. The underlying disease was acute
myelogenous leukemia in 7 patients and acute lympho-
blastic leukemia in 5 patients. Seven patients were in
complete remission (CR) status CR1, 4 were in CR2,
and 1 was in CR3. Themean pretransplantation weight
was 34.2 kg (range, 13-68 kg; median, 31.3 kg). Three
patients underwent MSD HSCT, and 9 underwent
MUD HSCT, 4 with a donor matched at 5 of 6 HLA
loci.Themean times to neutrophil and platelet engraft-
ment were 22 days (range, 12-34 days) and 27 days
(range, 16-40 days), respectively. The mean CD341
cell dose was 7  106 cells/kg (range, 3.75-14.5  106
cells/kg). Two patients had delayed neutrophil engraft-
ment, at 33 days and 34 days, both of whom underwent
MUDHSCTwith a donormatched at 5 of 6HLA loci.
These 2 patients received rabbit antithymocytic globu-
lin, had a CD341 cell dose of 5.3 and 4.6 106 cells/kg,
respectively, and received palifermin at 40 and
90 mg/kg/day, respectively. Grade II-IV GVHD was
seen in 1 patient; no patients had chronic GVHD.
With a mean follow-up of 2.7 years (range, 1.1-4.1
years), 10 of the 12 patients (83%) were surviving at
the time of this report, 9 (75%) without progression
of disease. One patient relapsed 9 months after
Table 1. Pharmacokinetics of Palifermin after Administration of the First (Day 211/29) and Last (Day +3) Doses
Day Number Dosage, mg/kg/day Clearance, mL/hour/kg, Mean ± SD AUC, ng/hour/mL, Mean ± SD Half-Life, Hours, Mean ± SD
211/29 12 40-90 1885 ± 497 40.5 ± 17.0 4.7 ± 0.7
3 40 2268 ± 285 17.9 ± 2.3 4.1 ± 0.6
3 60 1412 ± 554 46.7 ± 15.6 5.4 ± 0.8
6 90 1930 ± 403 48.8 ± 11.2 4.7 ± 0.5
+3 12 40-90 1901 ± 513 40.7 ± 18.1 4.5 ± 0.5
3 40 2243 ± 194 18.0 ± 1.7 4.1 ± 0.2
3 60 1541 ± 656 43.5 ± 15.1 4.6 ± 0.5
6 90 1911 ± 493 50.7 ± 14.0 4.7 ± 0.5
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alive and well. One patient died of progressive disease,
and another died from adenoviral sepsis.Toxicity
Palifermin at a dose of 90 mg/kg/day was tolerated,
with none of the 6 patients experiencing a DLT. All of
the 12 patients enrolled (100%) experienced at least
one adverse event, most of which were of NCI grade
1 or 2 severity. Six patients had maximal NCI grade 1
adverse events, 4 patients had maximal grade 2 adverse
events, and 2 patients had maximal grade 3 adverse
events. The most common adverse effect was macular
rash, which was seen in 8 patients (67%). Four of these
8 patients were at dose level 3, 2 patients were at level 2,
and 2 patients were at level 1. Rash occurred within 48-
72 after the first dose in all but 3 patients, who devel-
oped rash at 8, 10, and 14 days after the first dose.
The rash lasted for 48-72 hours in all patients but 1,
in whom it persisted for 7 days. It was localized to the
face, upper neck, shoulders, and groin and was classi-
fied as grade 1 in 3 patients, generalized grade 1 in 3 pa-
tients, and generalized grade 2 in 2 patients. The rash
wasmacular and pruritic and in 1 patient was accompa-
nied by grade 1 facial edema that persisted for 3 days.
Another patient had edema of the lip and eyelid of
grade 1 severity on day 25. Mucositis of NCI grade
1-2 severity developed in 3 of the 12 patients (25%),
on days12,13, and15. The median duration of total
parenteral nutrition administration was 41 days (range,
0-104 days), and the median cumulative dose of mor-
phine equivalents was 21mg (range, 0-6257mg) within
the first 100 days posttransplantation.
Grade 2-3 abdominal pain was noted in 2 patients,
beginning at 5 and 8 days after the first dose of palifer-
min and lasting for 3 days. One patient had grade 1 di-
arrhea and another had grade 2 vomiting on day 12.
Other adverse effects included grade 1 headache in 1 pa-
tient on day 16; grade 1-2 foot numbness on days 13
and 14 in 2 patients, lasting for 3 days; and grade 1
dry mouth and skin in 2 patients occurring 3 days after
the first dose and lasting for 7 days and 11 days.
Grade 1 elevation of aspartate aminotransferase
was seen in 3 patients, and grade 2 elevation in 1 pa-
tient, with onset between day27 and day22 and per-sistence for 1-2 days. Transient grade 1 elevation of
gamma glutamyl transpeptidase was seen in 4 patients
between days 12 and 16. One patient had grade 2 el-
evated alanine amino transferase and grade 3 hypoka-
lemia at dose level 3 on day 27, which resolved in 4
days. A transient grade 1 elevation of alanine amino
transferase was also seen in 2 patients with an onset
on day26, lasting for 2 days. No patients had a signif-
icant elevation in serum amylase or lipase. The patient
who received methotrexate for GVHD prophylaxis
had a grade 1 elevation of aspartate aminotransferase,
but did not develop mucositis.
Pharmacokinetic Profile
The pharmacokinetics of palifermin after adminis-
tration of the first dose (pretransplantation) and last
dose (posttransplantation), subdivided by dose level,
are summarized in Table 1. The observed concentra-
tion versus time along with the model-estimated
curves after administration of the first dose are shown
in Figure 1. Palifermin clearance was seen to increase
linearly with body weight (P \ 1024) (Figure 2).
Specifically, the intersubject variability of clearance
decreased from a 41% coefficient of variation (CV)
for non–weight-normalized clearance to a 29% CV
for weight-normalized clearance. The mean clearance
was 1893 mL/hour/kg, and this value did not change
significantly between the administration of the first
dose and the last dose (P 5 .80). In addition, the
mean elimination half-life was 4.6 hours, and this value
also did not change between the first and last doses
(P 5 .30). The clearance did not change significantly
(P 5 .40) over the studied dose range (40-90 mg/kg/
day), supporting linear pharmacokinetics over this
dose range. Approximately 97% of the exposure to pal-
ifermin occurred within the first 24 hours after dosing.DISCUSSION
Palifermin at a dose of 60 mg/kg/day administered
starting 3 days before conditioning and continuing for
3 days after stem cell infusion has been shown to re-
duce the incidence and duration of severe oral mucosi-
tis in adult patients with hematologic malignancies
undergoing autologous [12] or allogeneic HSCT
Figure 1. Concentration-versus-time plots for palifermin (ng/mL) after
the first dose (mg/kg), along with the posthoc fit to data (black, 40 mg/kg;
green, 60 mg/kg; red, 90 mg/kg).
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has been reported in some studies [15] but not in
others [16], albeit with a lower incidence of mucositis.
No beneficial effects on engraftment, GVHD preven-
tion, or survival have been demonstrated [10,14].
There are no published studies on the efficacy of
palifermin in children with cancer or on the
pharmacokinetics of palifermin in children.
In this study, a dose of 90 mg/kg/day starting 3 days
before conditioning and continuing for 3 days after
stem cell rescue did not reach the MTD. Only 3 of
12 patients (25%) had mucositis. This compares favor-
ably with the 37%, 57%, and 7% rates of mild, moder-
ate, and severe mucositis, respectively, reported in
patients receiving TBI with tacrolimus and sirolimus
for GVHDprophylaxis [2]. Paliferminmay confer mu-
cosal protection by inducing hypertrophy of themuco-
sal lining, as demonstrated by increased epithelialFigure 2. Clearance of palifermin (L/hour) with respect to body weight
in kilograms (open circles, day 211/29 dose; stars, day 13 dose).hyperplasia and expression of the proliferative marker
Ki-67 [17]. A 3-fold increase in Ki-67 staining 48 hours
after a single i.v. injection, defined as the histological
criterion for response, occurred in one-half of healthy
adult volunteers at a dose of 120 mg/kg and in the ma-
jority of subjects at a dose of $160 mg/kg [18].
Methotrexate given for GVHD prophylaxis im-
pairs mucosal regeneration after conditioning, wors-
ening and prolonging mucositis. Thus, epithelial cell
proliferation after palifermin may be impaired in pa-
tients receiving methotrexate. However, Blazar et al.
[14] reported no effect of a palifermin–methotrexate
interaction on the severity of mucositis in adults.
The sole patient who received methotrexate in the
present study did not develop mucositis.
Macular rash was the most common adverse
event, seen in 67% of our patients, similar to other
studies, but no case was of sufficient severity to con-
stitute a DLT or cause withdrawal from the study.
The rash was most likely related to the effects of
KGF on squamous epithelium of the skin and was re-
versible, short-lasting, and not associated with any re-
sidual changes in skin texture or pigmentation. Other
adverse effects included abdominal pain, vomiting,
diarrhea, headache, sensory neuropathy, and altered
liver enzymes, all of which were reversible and none
of which constituted a DLT. Studies on adults
undergoing autologous HSCT have reported rash
(55%), edema (27%), alteration in taste (22%), and
paresthesias (10%) as the most common side effects
[12]. Skin rash (94%), edema (78%), and local pain
(88%) were also the most common adverse events
in adults undergoing allogeneic HSCT who received
palifermin [14].
Palifermin exhibited linear pharmacokinetics in
children, and most of the drug was eliminated within
24-48 hours of administration. In our children, clear-
ance was faster (mean 6 SD, 1893 6 505 mL/hour/
kg) and AUC0-24 was lower (mean 6 SD, 40.6 6 17.6
ng/hour/mL) compared with healthy adult volunteers,
who had a reported clearance of 528 6 185 mL/hour/
kg with an AUC0-24 of 247 6 86 ng/hour/mL after a
single i.v. injection of 120 mg/kg and clearance of
661 6 162 mL/hour/kg with an AUC0-24 of 251 6 68
ng/hour/mL after a single i.v. injection of 160 mg/kg
[19]. The mean drug half-life was 5.22 hours and
4.89 hours at these 2 dose levels in those adults, compa-
rable to the mean half-life of 4.6 hours in our children.
A single collapsed dose of 180 mg/kg demonstrated
dose-linear pharmacokinetics compared with the stan-
dard dose in adults [19], although no randomized stud-
ies comparing the safety and efficacy of the 2 regimens
have been reported to date. Clearance in children was
not affected by repeat drug administration. The rela-
tionship between clearance of palifermin and body
weight shown in this study is a novel observation that
supports dosing by body weight.
1314 Biol Blood Marrow Transplant 18:1302-1314, 2012A. Srinivasan et al.In conclusion, palifermin at a dose of 90 mg/kg/day
was well tolerated in children with hematologic malig-
nancies after allogeneic HSCT. This is the first study
to detail the pharmacokinetics of palifermin in this
population. Randomized controlled trials in children
undergoing allogeneic HSCT with this dose are
needed to study the efficacy of palifermin in reducing
mucositis and its effect on thymic regeneration and
lymphocyte recovery. Palifermin has been found to re-
duce the incidence and duration of severe oral mucosi-
tis in adult patients undergoing autologous HSCT
[12]. Randomized trials to study the efficacy of palifer-
min in reducing mucositis in children undergoing
autologousHSCT usingmelphalan-based chemother-
apy may be beneficial.ACKNOWLEDGMENTS
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